Localized Prostate Cancer Treatment Options

Prostate cancer is the most common non-skin cancer among American men. Public health records indicate that one in six American men will be faced with the diagnosis of prostate cancer during their lifetime. On average, about 189,000 men are diagnosed with prostate cancer each year with about 32,000 cases being fatal.

Prostate-specific antigen (PSA) is a protein almost exclusively produced by the prostate. Initially approved by the Food and Drug Administration for the purpose of monitoring the status of prostate cancer in 1986, PSA has become an integral part of prostate cancer screening along with a digital rectal examination (DRE). Men with prostate cancer often have elevated levels of serum PSA which correlate with the extent of cancer spread. With the introduction of PSA screening in the late 1980s, there has been a dramatic rise in the number of men diagnosed with localized prostate cancer; approximately 80 percent of newly diagnosed men are considered to have a clinically organ-confined disease that is potentially amenable to cure.

Once diagnosed, men with localized prostate cancer face a difficulty choosing amongst various treatment options. Several factors come into play when selecting an appropriate therapy. The stage (extent of local spread) and grade (aggressiveness) of prostate cancer, as well as competing medical co-morbidities and age at diagnosis, can all influence the decision regarding the choice of therapeutic intervention.

Source: Prostate Cancer Treatment